相关实验视频
Updated: Aug 6, 2025

11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
9.5K
RHOJ控制了与EMT相关的化学疗法耐药性
Maud Debaugnies1,2, Sara Rodríguez-Acebes3, Jeremy Blondeau1
1Laboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Nature
|March 23, 2023
概括
经历了上皮转化为介质细胞 (EMT) 的癌细胞抵抗治疗. 小型GTPase RHOJ通过增强DNA修复来驱动这种耐药性,为化疗提供新的治疗点.
科学领域:
- 癌症学
- 分子生物学
- 癌症研究
背景情况:
- 癌症的耐药性导致患者死亡.
- 表皮转移到介质细胞转移 (EMT) 与各种癌症的治疗耐药性有关.
- 在EMT中介的耐药性背后的机制尚未完全理解.
研究的目的:
- 研究EMT对抗癌症疗法的作用.
- 确定驱动EMT相关疗法的分子机制.
- 探索RHOJ作为一种潜在的治疗点.
主要方法:
- 使用皮肤状细胞癌与自发EMT的小鼠模型.
- 在体内和体外进行功能增减研究.
- 进行全基因组转录和蛋白质分析.
- 研究RHOJ与核活性调节蛋白的相互作用.
主要成果:
- 对于多种抗癌疗法,EMT瘤细胞表现出高耐药性.
- 在EMT癌细胞中高度表达的小GTPase被确定为治疗耐药性的关键调节剂.
- RHOJ增强了对复制性压力的反应,并激活了DNA损伤反应途径,促进了化疗耐药性.
- 在RHOJ依赖的方式抑制了对化疗敏感的EMT细胞的活性聚合.
结论:
- RHOJ是EMT相关化疗耐药性的关键调节者.
- 通过增强DNA修复机制,RHOJ促进了耐药性.
- 在EMT阳性癌症中,向RHOJ或actin聚合可以克服治疗耐药性.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K

